Centre d'Estudis en Biofísica, Faculty of Medicine, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain.
Radiat Oncol. 2011 Apr 13;6:37. doi: 10.1186/1748-717X-6-37.
In the quest of a curative radiotherapy treatment for gliomas new delivery modes are being explored. At the Biomedical Beamline of the European Synchrotron Radiation Facility (ESRF), a new spatially-fractionated technique, called Minibeam Radiation Therapy (MBRT) is under development. The aim of this work is to compare the effectiveness of MBRT and broad-beam (BB) synchrotron radiation to treat F98 glioma rat cells. A dose escalation study was performed in order to delimit the range of doses where a therapeutic effect could be expected. These results will help in the design and optimization of the forthcoming in vivo studies at the ESRF.
Two hundred thousand F98 cells were seeded per well in 24-well plates, and incubated for 48 hours before being irradiated with spatially fractionated and seamless synchrotron x-rays at several doses. The percentage of each cell population (alive, early apoptotic and dead cells, where either late apoptotic as necrotic cells are included) was assessed by flow cytometry 48 hours after irradiation, whereas the metabolic activity of surviving cells was analyzed on days 3, 4, and 9 post-irradiation by using QBlue test.
The endpoint (or threshold dose from which an important enhancement in the effectiveness of both radiation treatments is achieved) obtained by flow cytometry could be established just before 12 Gy in the two irradiation schemes, whilst the endpoints assessed by the QBlue reagent, taking into account the cell recovery, were set around 18 Gy in both cases. In addition, flow cytometric analysis pointed at a larger effectiveness for minibeams, due to the higher proportion of early apoptotic cells.
When the valley doses in MBRT equal the dose deposited in the BB scheme, similar cell survival ratio and cell recovery were observed. However, a significant increase in the number of early apoptotic cells were found 48 hours after the minibeam radiation in comparison with the seamless mode.
为了寻找一种治疗脑胶质瘤的有效放射疗法,新的给药方式正在被探索。在欧洲同步辐射设施(ESRF)的生物医学光束线上,正在开发一种新的空间分割技术,称为微束放射治疗(MBRT)。这项工作的目的是比较 MBRT 和宽束(BB)同步辐射治疗 F98 胶质瘤大鼠细胞的效果。为了确定可能产生治疗效果的剂量范围,进行了剂量递增研究。这些结果将有助于在 ESRF 进行即将进行的体内研究的设计和优化。
将 20 万个 F98 细胞接种到 24 孔板的每个孔中,孵育 48 小时,然后用空间分割和无缝同步辐射 X 射线在几个剂量下照射。照射后 48 小时,通过流式细胞术评估每个细胞群体(存活、早期凋亡和死亡细胞,其中晚期凋亡和坏死细胞包括在内)的百分比,而通过 QBlue 测试分析照射后第 3、4 和 9 天存活细胞的代谢活性。
通过流式细胞术获得的终点(或两种放射治疗效果显著增强的阈值剂量)在两种照射方案中都可以在 12 Gy 之前确定,而通过 QBlue 试剂评估的终点(考虑到细胞恢复)在两种情况下都在 18 Gy 左右。此外,流式细胞术分析表明,由于早期凋亡细胞的比例较高,微束的效果更大。
当 MBRT 中的谷剂量等于 BB 方案中沉积的剂量时,观察到相似的细胞存活率和细胞恢复。然而,与无缝模式相比,照射后 48 小时发现微束照射的早期凋亡细胞数量显著增加。